Diplomat has access to dispense Arzerra, a cancer treatment with a recently expanded indication

FLINT, Mich. — Specialty pharmacy operator Diplomat has access to dispense Arzerra, a cancer treatment with a recently expanded indication, the company noted Tuesday.

The Food and Drug Administration recently expanded approval of Arzerra (ofatumumab) in combination with chlorambucil for the first-line treatment of chronic lymphocytic leukemia. Arzerra was previously approved by the FDA in October 2009 for the treatment of CLL resistant to other forms of chemotherapy.

Arzerra is distributed by GlaxoSmithKline.